Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial-Reference-Cited by-同舟云学术

Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial

Published:2010-10 Issue:10 Volume:11 Page:973-982
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Gimsing Peter,Carlson Kristina,Turesson Ingemar,Fayers Peter,Waage Anders,Vangsted Annette,Mylin Anne,Gluud Christian,Juliusson Gunnar,Gregersen Henrik,Hjorth-Hansen Henrik,Nesthus Ingerid,Dahl Inger Marie S,Westin Jan,Nielsen Johan Lanng,Knudsen Lene Meldgaard,Ahlberg Lucia,Hjorth Martin,Abildgaard Niels,Andersen Niels Frost,Linder Olle,Wisløff Finn

Publisher

Elsevier BV

Subject

Oncology

Reference39 articles.

1. The role of the Wnt-signalling antagonist DKK1 in the development of osteolytic bone lesions in multiple myeloma;Tian;N Engl J Med,2003

2. Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma;Lahtinen;Lancet,1992

3. A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma;McCloskey;Br J Haematol,1998

4. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma;Berenson;N Engl J Med,1996

5. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events;Berenson;J Clin Oncol,1998

Cited by 104 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Incidence and prevention of skeletal‐related events in multiple myeloma patients: A population‐based real‐world experience;eJHaem;2024-05-29

2. Pathophysiology and treatment of pain in multiple myeloma;Meditsinskiy sovet = Medical Council;2023-07-28

3. Management of Multiple Myeloma: A Review for General Practitioners in Oncology;Current Oncology;2023-04-22

4. The use of bone-modifying agents in multiple myeloma;Blood Reviews;2023-01

5. Preventing osteolytic lesions and osteomyelitis in multiple myeloma;Journal of Bone Oncology;2022-12